BioNexus Gene Lab Corp.
BGLC
$5.38
-$0.04-0.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.14% | -78.95% | 74.11% | -775.74% | 291.81% |
| Total Depreciation and Amortization | 4.25% | -6.98% | -12.42% | 55.87% | 6.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -173.00% | 134.48% | -24.92% | 71.81% | -1,841.69% |
| Change in Net Operating Assets | 63.87% | -170.86% | 62,757.14% | 99.79% | -8,466.67% |
| Cash from Operations | 10.46% | -1,080.66% | 95.22% | -117.09% | -1,707.26% |
| Capital Expenditure | -136.26% | -127.50% | 97.99% | -10,966.67% | 91.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.58% | -101.32% | 2,994.41% | -75.27% | 154.30% |
| Cash from Investing | -82.69% | -103.16% | 369.91% | -389.26% | 1,610.81% |
| Total Debt Issued | -- | -- | 99.29% | -212.31% | 552.04% |
| Total Debt Repaid | 44.44% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 391.67% | -- | -- |
| Cash from Financing | -11.11% | -100.61% | 173.52% | -213.68% | 552.04% |
| Foreign Exchange rate Adjustments | 399.30% | 110.52% | -172.47% | 1,417.48% | 40.75% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 30.76% | -594.11% | 112.64% | -167.95% | -503.16% |